In the updated NCCN Multiple Myeloma Guidelines, bortezomib plus dexamethasone is now a category 1 option as induction therapy for transplant candidates. Bortezomib, doxorubicin, and dexamethasone is now upgraded to category 1 from a category 2B option, as induction therapy for transplant candidates based on interim data from the HOVON-65/ GMMG-HD4 phase III trial. Bortezomib in combination with thalidomide and dexamethasone is now a category 1 option as induction therapy for transplant candidates.

Lenalidomide in combination with dexamethasone is now a category 1 recommendation in the NCCN Guidelines as an induction therapy option for both transplant and non-transplant candidates. Older regimens, including dexamethasone as a single agent, thalidomide with dexamethasone for both transplant and non-transplant candidates, DVD (liposomal doxorubicin, vincristine, and dexamethasone) for transplant candidates, and VAD (vincristine, doxorubicin, and dexamethasone) for non-transplant candidates, that were previously category 2A recommendations are now category 2B.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology�, please visit NCCN.org.

E-mail

Mark A A Size

	Quick Links
Clinical Practice Guidelines Drugs & Biologics Compendium Chemotherapy Order Templates Educational Events CME/CE Programs For Patients: NCCN.com Find an NCCN Member Institution Clinical Practice Guidelines Find Clinical Trials Permissions Requests Case Manager Training Member Institution Profiles Clinical Practice Guidelines Drugs & Biologics Compendium Permissions Requests Supporters and Exhibitors Oncology Research Program Corporate Council Permissions Requests NCCN Academy NCCN Business Insights, Research & Analytics NCCN Flash Updates NCCN Trends Surveys Permissions Requests

NCCN Website Supporters